Search

Arcutis Biotherapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.03 0.72

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.72

Max

25.07

Pagrindiniai rodikliai

By Trading Economics

Pajamos

26M

15M

Pardavimai

24M

130M

P/E

Sektoriaus vid.

112.636

57.366

Pelnas, tenkantis vienai akcijai

0.11

Pelno marža

11.558

Darbuotojai

354

EBITDA

23M

17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+47.58% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-130M

3.1B

Ankstesnė atidarymo kaina

24.31

Ankstesnė uždarymo kaina

25.03

Naujienos nuotaikos

By Acuity

50%

50%

167 / 340 reitingas Healthcare

Arcutis Biotherapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-25 19:36; UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

2026-08-24 19:16; UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

2026-08-21 19:56; UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

2026-08-20 19:51; UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

2026-08-19 19:26; UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

2026-08-18 19:56; UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

2026-08-14 20:06; UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

2026-08-13 19:36; UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

2026-08-12 19:46; UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

2026-08-11 23:46; UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

2026-08-10 19:36; UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

2026-08-07 23:31; UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

2026-08-06 22:16; UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

2026-08-05 23:02; UTC

News
Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

2026-08-04 19:46; UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

2026-08-03 21:01; UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

2026-07-31 20:03; UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

2026-07-30 23:51; UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

2026-07-29 19:19; UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

2026-07-28 18:06; UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

2026-07-27 16:07; UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

2026-07-24 19:16; UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

2026-07-21 19:46; UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

2026-07-20 20:14; UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Akcijų palyginimas

Kainos pokytis

Arcutis Biotherapeutics Inc Prognozė

Kainos tikslas

By TipRanks

47.58% į viršų

12 mėnesių prognozė

Vidutinis 36.57 USD  47.58%

Aukščiausias 40 USD

Žemiausias 34 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arcutis Biotherapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

167 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat